CD8A and lung disorder: We observed upward trends with two ELISpot ratios (RD1/PPD, RD1/antiCD3) and a FC (CD8+CD25+CD134+ [MTB300-nil] T-cells) assay in progressors vs. nonprogressors MAC lung disease, but P values did not attain level of significance by comparison across these subgroups (S2 Fig).